

7.1.3	Repeatability	417
7.1.4	Broad claims	417
7.2	Level of disclosure required for medical use – plausibility	418
7.2.1	Principles established by the case law	418
7.2.2	Evidence of therapeutic effect	420
a)	Plausibility of therapeutic effect	420
b)	Consequences of plausibility for whether post-published documents considered	421
c)	Consideration of post-published documents limited: cannot remedy a fundamental insufficiency of disclosure	423
d)	Whether opponents can cite post-published documents	424
e)	Types of evidence of a therapeutic effect and consideration of clinical trials	424
7.2.3	Pharmaceutical compositions	425
7.2.4	Field of pharmaceutical combinations (drug-drug interactions)	426
7.2.5	Medicament directed to a specific group of patients	426
7.3	Level of disclosure required for antibodies	426
7.4	Factors contributing to a finding of undue burden	429
7.5	Requirements relating to nucleotide and amino acid sequences	432
7.6	Deposit of living material	432
7.6.1	Substantive law questions	434
7.6.2	Procedural law questions	435
a)	Conversion into deposit under the Budapest Treaty	435
b)	Late submission of deposit number	435
c)	Biological material deposited by a person other than the applicant	435
8	The relationship between Article 83 and Article 84 EPC	436
8.1	Article 83 EPC and support from the description	436
8.2	Article 83 EPC and clarity of claims	438
8.2.1	Minority – or earlier – case law	439
8.2.2	Majority case law	439
a)	Currently predominant approach	439
b)	Case law before the now established approach	441
c)	Recent debate around the majority and minority lines of case law and alleged divergence in the case law	441
9	Evidence	441
9.1	Consequences of a strong or weak presumption for sufficiency of disclosure	442
9.2	Objection of insufficient disclosure rejected – examples	443
9.3	Burden of proof on the opponent – special cases	445
9.4	Taking account of doubts	445
9.5	Burden of proof wrongly allocated at first instance	446
9.6	Consequence of an invention going against generally accepted scientific principles	446
9.7	Miscellaneous – argument based on potential effects on competition rejected by the board	448